SEC to meet again to decide on full market nod for Covaxin, Covishield

The subject expert committee (SEC), a body under the Drugs Controller General of India (DCGI),will meet again to review applications filed by Bharat Biotech and Serum Institute of India for full market approval of their respective Covid vaccines – Covaxin and Covishield. The SEC had met on Friday but could not finish the review of the ‘huge amount of data’, people in the know told ET.

“The data is huge which has to be reviewed and it needs a considerable amount of time. The SEC will meet in the next 1-2 days to finish the review,” the same person said.

On Thursday, Bharat Biotech sought regular market approval from the drug regulator for its indigenous Covid-19 vaccine Covaxin, which is at present authorised for emergency use in the country.

“The review is going on and will continue. It can’t be done in a single day,” the person said, speaking on condition of anonymity.

The experts will meet again soon. “We will meet at the earliest- in the next 1-2 days,” he added.

A market authorisation label for a vaccine means it can be authorised for use without any reservations or conditions. Earlier, Serum Institute of India had also filed a similar application for Covishield.

In response to the application, the DCGI had sought more information which, according to sources, was submitted last week.

Covishield and Covaxin are the main Covid-19 vaccines used in the government’s vaccination drive. About 88% of the eligible population has received Covishield. Covaxin accounts for 12% of the total Covid-19 vaccines administered in India since January 2021. It is so far the only jab that is administered to youngsters in the age-group of 15-18 years, for whom vaccination started on January 3.

  • Related Posts

    • Pharma
    • December 23, 2024
    • 108 views
    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

    • Pharma
    • December 23, 2024
    • 132 views
    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt